The Department of Family Medicine is currently seeking participants for the following studies:
Ohio State’s Department of Family Medicine is currently enrolling for a research study for Type 2 diabetics who are inadequately controlled when not taking any medication for their diabetes. This study compares the effectiveness of treatment with sitagliptin (Januvia) and pioglitazone (Actos) taken together compared to taking sitagliptin (Januvia) and pioglitazone (Actos) separately. Participants will receive study related care, study medication, lab tests, glucose monitoring supplies, and diet and exercise counseling at no charge. Participation will last up to 65 weeks and there will be 11 visits to our clinic. If you are interested in learning more about this study, contact Paula Smailes at (614) 293-3644.
The Department of Family Medicine at Ohio State University is currently enrolling for a research study for Type 2 diabetics who are inadequately controlled on glipizide, Glimeperide, glyburide, or other sulfonylurea medication. This study evaluates the safety and effectiveness of a new diabetes drug, called dutogliptin, when taken in combination with Glimeperide, with or without Metformin, for their diabetes. Participants will receive study related care, study medication, lab tests, glucose monitoring supplies, and nutrition and exercise counseling at no charge. The research study will last for up to 38 weeks (approximately 10 months) and there will be 8 visits to our clinic. Participants will be paid up to $900 for completing the study. Qualified participants must:
If you are interested in learning more about this study, please contact Joan Allen, RN at (614) 366-6636 or joan.allen@osumc.edu.
The Rheos Pivotal Trial is testing the efficacy of an implantable electronic device to lower blood pressure. The power pack is inserted much like a pacemaker. Two leads, one to each carotid sinus then sends electrical impulses to the baroreceptors located within the sinus. The brain interprets these signals as an exceedingly high blood pressure and activates the bodies normal modulating mechanisms to reduce the pressure. In essence, it "tricks" the brain into lowering blood pressure. To qualify for this study, you must:
For more information about these trials, or if you are interested in participating, please contact Paula Smailes at 614-293-3644 or email at paula.smailes@osumc.edu.
The Department of Family Medicine at Ohio State University is currently enrolling for a research study for Type 2 diabetics who are inadequately controlled when 1) taking metformin alone, or 2) taking only one sulfonylurea drug, or 3) are currently not taking any medication for their diabetes. This study compares the effectiveness of treatment with Sitagliptin (Januvia™) and pioglitazone (Actos™) taken together compared to taking Sitagliptin (Januvia™) and pioglitazone (Actos™) separately. Participants will receive study related care, study medication, lab tests, glucose monitoring supplies, and diet and exercise counseling at no charge. Participation will last for up to 65 weeks and there will be 11 visits to our clinic.
If you are interested in learning more about this study, please contact Paula Smailes at (614) 293-3644 or paula.smailes@osumc.edu.
The Department of Family Medicine at Ohio State University is currently enrolling for a research study for people with Atrial Fibrillation.
Atrial Fibrillation is an abnormal heart rhythm that involves the two upper chambers of the heart known as the atria. It can often be identified by taking a pulse and finding that the heartbeats don't occur at regular intervals. This study looks to see how well a drug treats Atrial Fibrillation when compared to the drug called Coumadin. Participants will receive study related care, study medication and lab tests at no charge. Participation will last up to 2-3 years and participants may receive up to $1,120.
If you are interested in learning more about this study, please contact Paula Smailes at (614) 293-3644 or paula.smailes@osumc.edu